A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation

Analytical Biochemistry

Volumn 448, Issue 1, 2014, Pages 23-29

  Shapiro, Adam B ^a   Austin, Caroline A ^b  

^a ASTRAZENECA   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Fluorescence anisotropy; High throughput assay; Topoisomerase; Topoisomerase II ; Topoisomerase II

Indexed keywords

ANISOTROPY; DNA; DRUG INTERACTIONS; FLUORESCENCE; TOXICITY; TRANSCRIPTION;

ANTIBACTERIAL COMPOUNDS; BIOCHEMICAL ASSAY; FLUORESCENCE ANISOTROPY; HIGH-THROUGHPUT ASSAYS; HUMAN TOPOISOMERASE; IDENTICAL CONDITIONS; TOPOISOMERASE II; TOPOISOMERASES;

ENZYME INHIBITION;

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ADENOSINE TRIPHOSPHATE; AMSACRINE; BISANTRENE; CIPROFLOXACIN; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; DOXORUBICIN; ENZYME INHIBITOR; EPIRUBICIN; ETOPOSIDE; GEMIFLOXACIN; GENISTEIN; LEVOFLOXACIN; MERBARONE; MITOXANTRONE; RAZOXANE; SURAMIN; TENIPOSIDE; UNCLASSIFIED DRUG; XK 469;

ANISOTROPY; ARTICLE; CONTROLLED STUDY; DNA SUPERCOILING; DRUG POTENCY; DRUG SELECTIVITY; EMISSION ANISOTROPY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING;

FLUORESCENCE ANISOTROPY; HIGH-THROUGHPUT ASSAY; TOPOISOMERASE; TOPOISOMERASE IIΑ; TOPOISOMERASE IIΒ;

ADENOSINE TRIPHOSPHATE; ANTIGENS, NEOPLASM; BIOCATALYSIS; DNA TOPOISOMERASES, TYPE II; DNA, SUPERHELICAL; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FLUORESCENCE POLARIZATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KINETICS;

EID: 84891511978     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2013.11.029     Document Type: Article

References (45)

1. J.J. Champoux DNA topoisomerases: structure, function, and mechanism Annu. Rev. Biochem. 70 2001 369 413 (Pubitemid 32662215)
2. J.C. Wang Cellular roles of DNA topoisomerases: a molecular perspective Nat. Rev. Mol. Cell Biol. 3 2002 430 440 (Pubitemid 34685700)
3. K. Chikamori, A.G. Grozav, T. Kozuki, D. Grabowski, R. Ganapathi, and M.K. Ganapathi DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy Curr. Cancer Drug Targets 10 2010 758 771
4. K. Drlica, and M. Malik Fluoroquinolones: action and resistance Curr. Topics Med. Chem. 3 2003 249 282
5. A. Maxwell, and D.M. Lawson The ATP-binding site of type II topoisomerases as a target for antibacterial drugs Curr. Topics Med. Chem. 3 2003 283 303
6. C.A. Austin, and K.L. Marsh Eukaryotic DNA topoisomerase IIβ BioEssays 20 1998 215 226
7. A. Vávrová, and T. Šimunek DNA topoisomerase IIβ: a player in regulation of gene expression and cell differentiation Int. J. Biochem. Cell Biol. 44 2012 834 837
8. C.A. Austin, J.-H. Sng, S. Patel, and L.M. Fisher Novel HeLa topoisomerase II is the IIβ isoform: complete coding sequence and homology with other type II topoisomerases Biochim. Biophys. Acta 1172 1993 283 291 (Pubitemid 23079954)
9. K. Padget, A.D.J. Pearson, and C.A. Austin Quantitation of DNA topoisomerase IIα and β in human leukaemia cells by immunoblotting Leukemia 14 2000 1997 2005
10. N. Akimitsu, K. Kamura, S. Toné, A. Sakaguchi, A. Kikuchi, H. Hamamoto, and K. Sekimizu Induction of apoptosis by depletion of DNA topoisomerase IIα in mammalian cells Biochem. Biophys. Res. Commun. 307 2003 301 307 (Pubitemid 36818869)
11. S. Dereuddre, C. Delaporte, and A. Jacquemin-Sablon Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors Cancer Res. 57 1997 4301 4308 (Pubitemid 27413439)
12. Y.L. Lyu, and J.C. Wang Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIβ Proc. Natl. Acad. Sci. USA 100 2003 7123 7128 (Pubitemid 36706403)
13. X. Yang, W. Li, E.D. Prescott, S.J. Burden, and J.C. Wang DNA topoisomerase IIβ and neural development Science 287 2000 131 134
14. F. Errington, E. Willmore, M.J. Tilby, L. Li, G. Li, W. Li, B.C. Baguley, and C.A. Austin Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation Mol. Pharmacol. 56 1999 1309 1316
15. I.G. Cowell, Z. Sondka, K. Smith, K.C. Lee, C.M. Manville, M. Sidorczuk-Lesthuruge, H.A. Rance, K. Padget, G.H. Jackson, N. Adachi, and C.A. Austin Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity Proc. Natl. Acad. Sci. USA 109 2012 8989 8994
16. I.G. Cowell, and C.A. Austin Mechanism of generation of therapy related leukemia in response to anti-topisomerase II agents Int. J. Environ. Res. Public Health 9 2012 2075 2091
17. A.M. Azarova, Y.L. Lyu, C.-P. Lin, Y.-C. Tsai, J.Y.-N. Lau, J.C. Wang, and L.F. Liu Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies Proc. Natl. Acad. Sci. USA 104 2007 11014 11019 (Pubitemid 47175218)
18. S. Zhang, X. Liu, T. Bawa-Khalfe, L.-S. Lu, Y.L. Lyu, L.F. Liu, and E.T.H. Yeh Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat. Med. 18 2012 1639 1642
19. Y.L. Lyu, J.E. Kerrigan, C.-P. Lin, A.M. Azarova, Y.-C. Tsai, Y. Ban, and L.F. Liu Topoisomerase IIβ-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane Cancer Res. 67 2007 8839 8846 (Pubitemid 47437460)
20. W. Chen, J. Qiu, and Y. Shen Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs Drug Discov. Ther. 6 2012 230 237
21. D. Perrin, B. van Hille, and B.T. Hill Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents Biochem. Pharmacol. 56 1998 503 507 (Pubitemid 28468587)
22. E.L. Meczes, K.L. Marsh, L.M. Fisher, M.P. Rogers, and C.A. Austin Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast Cancer Chemother. Pharmacol. 39 1997 367 375 (Pubitemid 27047483)
23. R.M. Turnbull, E.L. Meczes, M. Perenna Rogers, R.B. Lock, D.M. Sullivan, G.J. Finlay, B.C. Baguley, and C.A. Austin Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIα and β Cancer Chemother. Pharmacol. 44 1999 275 282 (Pubitemid 29402196)
24. F.H. Drake, G.A. Hofmann, H.F. Bartus, M.R. Mattern, S.T. Crooke, and C.K. Mirabelli Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II Biochemistry 28 1989 8154 8160 (Pubitemid 19252897)
25. H. Gao, K.-C. Huang, E.F. Yamasaki, K.K. Chan, L. Chohan, and R.M. Snapka XK469, a selective topoisomerase IIβ poison Proc. Natl. Acad. Sci. USA 96 1999 12168 12173
26. G. Boos, and H. Stopper Genotoxicity of several clinically used topoisomerase II inhibitors Toxicol. Lett. 116 2000 7 16 (Pubitemid 30440762)
27. D.J. Smart, and A.M. Lynch Evaluating the genotoxicity of topoisomerase-targeted antibiotics Mutagenesis 27 2012 359 365
28. A. Shapiro, H. Jahić, S. Prasad, D. Ehmann, J. Thresher, N. Gao, and L. Hajec A homogeneous, high-throughput fluorescence anisotropy-based DNA supercoiling assay J. Biomol. Screen. 15 2010 1088 1098
29. A.B. Shapiro A high-throughput-compatible, fluorescence anisotropy-based assay for ATP-dependent supercoiled DNA relaxation by human topoisomerase IIα Biochem. Pharmacol. 85 2013 1269 1277
30. K.M. Jude, A. Hartland, and J.M. Berger Real-time detection of DNA topological changes with a fluorescently labeled cruciform Nucl. Acids Res. 41 2013 e133
31. C.A. Austin, K.L. Marsh, R.A. Wasserman, E. Willmore, P.J. Sayer, J.C. Wang, and L.M. Fisher Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ J. Biol. Chem. 270 1995 15739 15746
32. A.B. Shapiro, G.K. Walkup, and T.A. Keating Correction for interference by test samples in high-throughput assays J. Biomol. Screen. 14 2009 1008 1016
33. J.H. Zhang, T.D.Y. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high-throughput screening assays J. Biomol. Screen. 4 1999 67 73 (Pubitemid 29278954)
34. K.L. Gilroy, and C.A. Austin The impact of the C-terminal domain on the interaction of human DNA topoisomerase IIα and β with DNA PLoS ONE 6 2011 e14693
35. E.L. Meczes, K.L. Gilroy, K.L. West, and C.A. Austin The impact of the human DNA topoisomerase II C-terminal domain on activity PLoS ONE 3 2008 e1754
36. L.E. Lawrence, P. Wu, K.E. Gouveia, A. Card, M. Casperson, K. Denbleyker, and J.F. Barrett The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues J. Antimicrob. Chemother. 48 2001 195 201 (Pubitemid 32755279)
37. S.L. McGovern, E. Caselli, N. Grigorieff, and B.K. Shoichet A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening J. Med. Chem. 45 2002 1712 1722 (Pubitemid 34293537)
38. S.L. McGovern, B.T. Helfand, B. Feng, and B.K. Shoichet A specific mechanism of nonspecific inhibition J. Med. Chem. 46 2003 4265 4272 (Pubitemid 37153008)
39. S. Classen, S. Olland, and J.M. Berger Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 Proc. Natl. Acad. Sci. USA 100 2003 10629 10634 (Pubitemid 37140080)
40. S.K. Morris, C.L. Baird, and J.E. Lindsley Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193 J. Biol. Chem. 275 2000 2613 2618 (Pubitemid 30082028)
41. 2-terminal fragments of yeast DNA topoisomerase II J. Biol. Chem. 274 1999 21688 21694
42. K. Bojanowski, S. Lelievre, J. Markovits, J. Couprie, A. Jacquemin-Sablon, and A. Kragh Larsen Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells Proc. Natl. Acad. Sci. USA 89 1992 3025 3029
43. M. Sander, and T.-S. Hsieh Double strand DNA cleavage by Type II DNA topoisomerase from Drosophila melanogaster J. Biol. Chem. 258 1983 8421 8428
44. K.M. Tewey, T.C. Rowe, L. Yang, B.D. Halligan, and L.F. Liu Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 226 1984 466 468 (Pubitemid 14012819)
45. M.J. Robinson, A.H. Corbett, and N. Osheroff Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II Biochemistry 32 1993 3638 3643 (Pubitemid 23126939)